Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Open Access

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors

  • Mark A Rosenberg1 and
  • Jason Williams2
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P142

https://doi.org/10.1186/2051-1426-3-S2-P142

Published: 4 November 2015

Background

Image guided cryoablation of cancer destroys tumor tissue and can activate tumor-specific T cells by increasing the presentation of tumor antigens and causing the release of “Danger signals” to stimulate the immune system. However, the development of a systemic anti-cancer immune response may be restrained by immune check-point inhibitors. In recent years, the U.S. Food and Drug Administration–approved antibody drug ipilumimab, nivolumab and pembrolizumab as inhibitors of CTLA-4 and PD-1. By blocking these immune check-point receptors, these antibodies can promote tumor rejection, but their full application has yet to be fully determined.

Methods

In our human case studies, we offer a proof-of-concept in multiple tumor types that intra-tumoral CTLA-4 and PD-1 blockade combined with cryoablation of a primary tumor can cause regression of secondary tumors at a distant site.

Results

From past clinical experience, we know that secondary tumors are unlikely to be affected by cryoablation alone, the combination treatment was sufficient to cause complete cancer regression and tumor rejection. Cryoablation is currently used to treat a targeted tumor, our results suggest that combination therapy with CTLA-4 and PD-1 blockade, by direct injection into the ablated tumor, will enhance anti-tumor immunity and rejection of tumor metastases.

Authors’ Affiliations

(1)
Cancer Immune Biologics
(2)
Cancer Immune Biologics

Copyright

© Rosenberg and Williams 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement